Skip to main content
. Author manuscript; available in PMC: 2015 Aug 1.
Published in final edited form as: Clin Pharmacol Ther. 2014 Apr 29;96(2):182–191. doi: 10.1038/clpt.2014.93

Table 3.

Efficacy

Number of patients (%)
Arm A (n=26) Arm B (n=26) All (n=52)*
DCR at 3 months 6 (23) 6 (23) 12 (24)
  PR 1 (4) 0 1 (2)
  SD 5 (19) 6 (23) 11 (22)
  PD 20 (77) 20 (77) 40 (78)
Arm A (n=28) Arm B (n=27) All (n=55)**
TTP, months
  Median (95% CI) 2.8 (2.5–3.1) 2.4 (1.5–2.7) 2.6 (1.9– 2.8)
  Range 0.6–14.4 0.3–20.2 0.3–20.2
  1 year progression free rate (%) 10 4 7
Survival, months
  Median 5.3 5.2 5.3
  Range 0.9–37.4 1.3–42.8 0.9–42.8
  1 year survival rate (%) 30 26 28
*

responses based on evaluable patients

**

based on all 55 treated patients